Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection (Q36354268)

13 August 2017

Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection (English)

1 reference

13 August 2017

1 reference

Weber JS

1

1 reference

13 August 2017

Jay G

series ordinal

2

1 reference

13 August 2017

Tanaka K

series ordinal

3

1 reference

13 August 2017

Rosenberg SA

series ordinal

4

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 December 1987

1 reference

Journal of Experimental Medicine

13 August 2017

1 reference

13 August 2017

166

1 reference

13 August 2017

6

1 reference

13 August 2017

1716-1733

1 reference

Gamma-interferon induces expression of the HLA-D antigens on normal and leukemic human myeloid cells

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

MHC-Restricted Cytotoxic T Cells: Studies on the Biological Role of Polymorphic Major Transplantation Antigens Determining T-Cell Restriction-Specificity, Function, and Responsiveness

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

Differential expression of H-2 gene products in tumour cells in associated with their metastatogenic properties

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

Absence of human leukocyte antigen molecules in skin tumors and some cutaneous appendages: Evidence using monoclonal antibodies

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

Noncytocidal mechanisms of action of tumor necrosis factor-alpha on human tumor cells: enhancement of HLA gene expression synergistic with interferon-gamma.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2188791

Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2

22 September 2018

1 reference

12 December 2020

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

12 December 2020

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

12 December 2020

Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo

1 reference

12 December 2020

Lack of expression of HLA antigens on choriocarcinoma cell lines

1 reference

12 December 2020

Alloreactive T-cell clones. Ly phenotypes predict both function and specificity for major histocompatibility complex products

1 reference

12 December 2020

Abrogation of metastatic properties of tumour cells by de novo expression of H–2K antigens following H–2 gene transfection

1 reference

12 December 2020

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells

1 reference

12 December 2020

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types

1 reference

12 December 2020

Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Identifiers

DOI

10.1084/JEM.166.6.1716

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

3500265

1 reference